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Pancreatic ductal adenocarcinoma (PDAC) is characterized by the
presence of abundant desmoplastic stroma primarily composed of
cancer-associated fibroblasts (CAFs). It is generally accepted that
CAFs stimulate tumor progression and might be implicated in drug
resistance and immunosuppression. Here, we have compared the
transcriptional profile of PDGFRα+ CAFs isolated from genetically
engineered mouse PDAC tumors with that of normal pancreatic fi-
broblasts to identify genes potentially implicated in their protumori-
genic properties. We report that the most differentially expressed
gene, Saa3, a member of the serum amyloid A (SAA) apolipoprotein
family, is a key mediator of the protumorigenic activity of PDGFRα+
CAFs. Whereas Saa3-competent CAFs stimulate the growth of tumor
cells in an orthotopic model, Saa3-null CAFs inhibit tumor growth.
Saa3 also plays a role in the cross talk between CAFs and tumor cells.
Ablation of Saa3 in pancreatic tumor cells makes them insensitive to
the inhibitory effect of Saa3-null CAFs. As a consequence, germline
ablation of Saa3 does not prevent PDAC development in mice. The
protumorigenic activity of Saa3 in CAFs is mediated by Mpp6, a
member of the palmitoylated membrane protein subfamily of the
peripheral membrane-associated guanylate kinases (MAGUK). Fi-
nally, we interrogated whether these observations could be trans-
lated to a human scenario. Indeed, SAA1, the ortholog of murine
Saa3, is overexpressed in human CAFs. Moreover, high levels of
SAA1 in the stromal component correlate with worse survival. These
findings support the concept that selective inhibition of SAA1 in CAFs
may provide potential therapeutic benefit to PDAC patients.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the mostlethal malignancies worldwide, and it is projected to be the
second leading cause of cancer-related deaths by 2030 (1, 2).
Despite extensive research efforts over the past decades, there
have been few improvements in the diagnosis or treatment of the
disease. Most of the patients are diagnosed at an advanced stage,
when the tumor is unresectable and metastasis is already present.
Furthermore, current therapies are based on chemotherapy
agents and provide only a modest increase in survival, high-
lighting the need for new therapeutic strategies (3).
PDAC is characterized by an abundant desmoplasia that
constitutes up to 90% of the total tumor volume. This stroma is
composed mainly (around 90%) of cancer-associated fibroblasts
(CAFs) (4, 5). CAFs secrete extracellular matrix (ECM) proteins
as well as soluble factors (such as chemokines and cytokines) that
stimulate cancer progression (6–8). Furthermore, it has also
been reported that CAFs mediate drug resistance and immu-
nosuppression (9–12). Hence, CAFs may represent an important
target for anticancer therapy.
This concept has been recently challenged by two independent
studies in which elimination of the stroma in genetically engi-
neered mouse (GEM) PDAC models resulted in more aggressive
tumors and reduced survival (13–15). However, CAFs are a
heterogeneous population (6, 8); thus, it is conceivable that
different CAFs may have differential pro- and antitumorigenic
roles. Therefore, a better understanding of the role that these
CAF subpopulations play in PDAC progression may allow their
selective reprogramming to thwart their protumorigenic effects
without having to resort to their physical elimination.
To this end, we have characterized the transcriptome of a
protumorigenic subpopulation of CAFs defined by the expres-
sion of the platelet-derived growth factor receptor alpha
(PDGFRα). These studies have revealed a series of highly
overexpressed genes in these cells compared with those
expressed in fibroblasts present in normal pancreata. The top
overexpressed gene in our studies was Saa3, a member of the
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acute-phase serum amyloid A (SAA) apolipoprotein family
found associated with high-density lipoproteins in plasma (16).
SAA proteins are expressed mainly in the liver, although their
expression has also been described in synovial tissue, placenta,
adipocytes, and smooth muscle cells (17). Expression of SAA
members is induced in injured tissues and cells, including ath-
erosclerotic plaques and rheumatoid synovitis, as well as in the
brain of Alzheimer’s patients and in certain tumor cells (18).
Accumulation of these acute-phase proteins in the blood is also
observed during chronic inflammation and cancer. Moreover,
they are considered to be biomarkers whose expression is as-
sociated with tumor progression and reduced survival in many
human cancers (18, 19).
Here, we report that Saa3 plays a key role in inducing the
protumorigenic properties of PDGFRα+ CAFs. Unfortunately,
Saa3 is also essential for the protumorigenic cross talk between
these CAFs and their neighboring tumor cells, a property that
may limit its potential therapeutic effect to those strategies that
could specifically target Saa3 activity in CAFs. Importantly, we
also report here that the protumorigenic activity of Saa3 is reg-
ulated by membrane palmitoylated protein 6 (Mpp6), a member
of the peripheral membrane-associated guanylate kinases
(MAGUK). Since this regulatory interaction between Saa3 and
Mpp6 appears to take place only in CAFs, these observations
open the door to the design of future therapeutic strategies by
controlling the levels of expression of Mpp6.
Results
PDGFRα+ CAFs Promote Tumor Growth. To characterize the pop-
ulations of CAFs present in PDAC, we used a GEM tumor
model previously generated by M. Barbacid’s laboratory, the
K-Ras+/LSLG12Vgeo;Trp53lox/lox;Elas-tTA/tetO-Cre compound strain,
in which we can selectively induce the expression of a resident
K-RasG12V oncogene and disable the p53 tumor suppressor in
acinar cells during late embryonic development (20). In this
study, we added a Rosa26LSLEYFP allele to have a color marker
(EYFP) to identify those cells carrying the K-RasG12V/p53-null
tumor-initiating mutations. These mice, designated as “KPeCY,”
develop PDAC tumors with complete penetrance and an average
latency of 3–4 mo. More importantly, they recapitulate the human
disease, including the formation of a massive stromal desmoplasia
made up of heterogeneous CAF populations. Furthermore, this
stromal remodeling is characterized by a chronic inflammatory re-
sponse. Therefore, we studied the functional implications of tumor-
promoting inflammation mediated by CAFs by performing a
comparative expression profiling of PDGFRα+ CAFs and
PDGFRα+ normal pancreatic fibroblasts (NPFs) as previously de-
scribed (21).
Immunofluorescence analysis of stromal tissue with antibodies
elicited against α-smooth muscle actin (αSMA) and PDGFRα
revealed that, whereas most stromal cells of KPeCY tumors expressed
αSMA, only a subpopulation contained PDGFRα (Fig. 1A). FACS
analysis of fresh tumors showed at least four distinct populations of
stromal cells (Fig. 1B). Whereas one population only expressed
αSMA (39% of the total), another population representing 36% of
the cells contained both markers, αSMA and PDGFRα. We also
identified two additional populations represented by those cells that
expressed only PDGFRα (9%) and those that did not express either
marker or expressed them at very low levels (16%) (Fig. 1B).
Next, we sorted PDGFRα+/EYFP−/CD45−/CD31− stromal cells
from PDAC tumors of KPeCY mice as well as from normal pan-
creata of control Elas-tTA/tetO-Cre;Rosa26+/LSLEYFP animals (Fig.
1C and Fig. S1A). These cells represented 21% and 15% of the
total cells, respectively. Cultures derived from cell population
retained αSMA and PDGFRα expression and displayed the spindle
shape characteristic of fibroblasts (Fig. 1D). The fibroblastic nature
of these cells was further verified by the expression of fibroblast-
specific genes including FAP, Vimentin, and PDGFRβ as well as by
the lack of immune (CD45, CD68) and tumor (CK19, EpCAM)
cell markers (Fig. 1C and Fig. S1B). These results indicate that the
PDGFRα+ stromal cells isolated from KPeCY tumors represent
CAFs, whereas those obtained from normal pancreata represent
NPFs. The latter had slightly higher levels of αSMA than CAFs, a
property that has been proposed to represent a marker of myofi-
broblast activation (Fig. S1C) (8). Herein, these PDGFRα+ cell
populations are designated simply as “CAFs” and “NPFs.”
To determine whether these CAFs can promote tumorigenesis,
we compared their tumor-supporting capabilities with those of
PDGFR































































































































































Fig. 1. Protumorigenic properties of PDGFRα+ CAFs. (A, Left) Immunofluores-
cence staining with anti-αSMA (green) and anti-PDGFRα (red) antibodies and
with EYFP (yellow) of a KPeCY PDAC tumor. (Right) Higher magnification of
PDGFRα+ (red) and EYFP+ (yellow) cells. (Scale bars, 100 μm.) (B, Left) FACS
analysis of fresh tumor samples with CD31/CD45 and EYFP markers. (Right) FACS
analysis of CD31−/CD45−/EYFP− cells with anti-αSMA and anti-PDGFRα anti-
bodies. The percentages of αSMA and PDGFRα single-positive cells as well as
αSMA/PDGFRα double-negative and double-positive cells are indicated. (C) Cell
sorting of KPeCY PDAC tumors and normal pancreata from control Elas-tTA/
tetO-Cre;Rosa26+/LSLEYFP mice selected with DAPI, anti-CD31 and anti-CD45, anti-
EpCAM, and anti-PDGFRα and EYFP. The percentages of NPFs and CAFs are
indicated. (D) Immunofluorescence staining of sorted CAFs and NPFs after ex-
pansion in culture with anti-αSMA (green) and anti-PDGFRα (red) antibodies.
(Scale bars, 50 μm.) (E) Growth of PDAC tumor cells (0.5 × 106) injected s.c. into
immunocompromised mice either alone (red circles) or coinjected with the same
amount of CAFs (black circles) or NPFs (open circles). *P < 0.05; **P < 0.001.
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NPFs using in vivo assays. EYFP+-sorted PDAC tumor cells (0.5×106)
isolated from tumor-bearing KPeCY mice were s.c. inoculated alone
(n = 4) or in combination with CAFs (0.5 × 106) (n = 4) or NPFs (0.5×
106) (n = 4) into the flanks of immunocompromised mice. Whereas
CAFs stimulated tumor growth by as much as 76%, NPFs inhibited the
proliferation of the pancreatic tumor cells by as much as 65% (Fig. 1E).
These results illustrate the protumorigenic activity of the subpopulation
of CAFs used in this study.
Comparative Transcriptional Profiles of CAFs vs. NPFs. To understand
the genetic bases responsible for the tumor-promoting activity of
CAFs, we performed a comparative study of the transcriptome
profiles of freshly isolated CAFs (n = 5) with those of NPFs (n =
3) by RNA sequencing (RNAseq) analysis. As illustrated in Fig.
2A, CAFs displayed a strong proinflammatory profile that in-
cluded genes encoding competent cascade-related and acute-
phase proteins (C4b, Hp, and A2m), cytokines (Il1b and Il6),
chemokines (Cxcl1 and Ccl22), other interleukins (Il10), and
members of the TNF family associated with the innate immune
response. Furthermore, Gene Set Enrichment Analysis (GSEA)
confirmed the up-regulation of the immune cell-recruiting com-
plement cascade [false-discovery rate (FDR) ≤ 0001], IL1R
(FDR = 0.001), and the Jak-Stat (FDR = 0.025) pathways in
CAFs. This analysis also identified cytokine/receptor signaling as
one of the most significantly up-regulated pathways in CAFs
compared with NPFs (Fig. 2B and Fig. S2A). In addition, we
observed a high enrichment in cell-to-cell junction pathways sug-
gesting the presence of active contact-mediated signaling in CAFs
(Fig. 2B and Fig. S2A), a property that may have an important role
in tumor promotion (22). CAFs also displayed up-regulation of
TGFβ- and Hedgehog-signaling pathways as well as ECM/receptor
interactions (Fig. S2A), a set of transcriptional changes thought to
result from their cross talk with the tumor cells (13, 23).
Down-regulated hallmarks include oxidative phosphorylation,
suggesting that CAFs have undergone metabolic reprogramming
and oxidative stress (Fig. S2A). The latter was further supported
by the significant down-regulation of genes involved in peptide
elongation, translation, and protein metabolism, hallmarks of
stress responses indicating mitochondrial dysfunction. We also
observed significant reduction of P53-signaling–related genes,
suggesting cell death evasion (24, 25). These results, taken to-
gether, support the concept that the CAFs used in this study
possess a unique secretory-inflammatory gene signature with
emphasis on the activation of the innate immune response (Fig.
2) as well as impaired oxidative phosphorylation (Fig. S2A).
SAA3 Is Overexpressed in CAFs. The top up-regulated gene in CAFs
compared with NPFs was a gene encoding the SAA3 protein,
Saa3 (Fig. 2A). These results were confirmed by qRT-PCR (Fig.
S2B). Saa3 transcripts were also up-regulated compared with
tumor cells as well as with other normal tissues such as pancreas
or liver (Fig. S2B). Little is known regarding the putative role of
Saa3 in cancer, although Hansen et al. (26) have suggested
protumorigenic activity. During inflammation, Saa3 expression is
induced by Il-1β, Tnfα, and Il-6 through NFκB signaling. In turn,
Saa3 can also activate these cytokines (26, 27). Consistently, Il-
1β, Tnfα, and Il-6, as well as the NFκB pathway, were found to be
significantly up-regulated in our dataset (Fig. 2A and Fig. S2A).
PDAC Development in Saa3-KO Mice. To interrogate the effect of
ablating Saa3 expression in PDAC development, we incorporated
Saa3-null alleles to the KPeCY strain. As previously reported,
germline ablation of Saa3 does not induce detectable phenotypic
alterations (28). Moreover, Saa3-null K-Ras+/LSLG12Vgeo;Elas-tTA/
tetO-Cre mice displayed the same number of pancreatic intra-
epithelial neoplasia (PanIN) lesions and PDAC tumors as Saa3-
competent animals (Fig. S3A). Likewise, KPeCY mice carrying
either wild-type Saa3 alleles (n = 18) or Saa3-null alleles (n = 20)
developed PDAC with 100% penetrance, succumbing to pancre-
atic tumors before 23 wk of age with median survivals of 15 and
16 wk, respectively. These observations, taken together, indicate
that the absence of Saa3 expression from their germline has no
significant effect on tumor development (Fig. S3B).
However, Saa3-null tumors had a higher proportion of EYFP+
tumor cells and displayed less dense fibrotic stroma, albeit these
differences were not statistically relevant by FACS analysis (Fig.
S3C). Histological analysis revealed that Saa3-null tumor cells were
more packed than in control tumors and exhibit a significant re-
organization of their ECM as revealed by their reduced levels of
collagen content (Fig. 3A and Table 1). Interestingly, we did not
observe a significant reduction in the PDGFRα+ population, in-
dicating that the reduced stromal content is not due to the loss of this
CAF subpopulation (Fig. S3D). Moreover, we observed a significant
increase in the levels of macrophage infiltration in the Saa3-null
tumors (12.5% vs. 3.8% of total area) (Fig. 3B and Table 1). The
increase in tumor-infiltrating macrophages was observed in both the
antitumorigenic M1 and the protumorigenic M2 populations (Fig.
3C). However, this increase appeared to be more pronounced in the
M2 population, which has been associated with worse clinical out-
come in PDAC patients (29). In contrast, there were no obvious
differences in the amount or localization of neutrophils or T and B
lymphocytes (Table 1 and Fig. S3E). Saa3-null tumors also displayed
a significantly elevated number of endothelial CD31+ cells, in-
dicating increased vessel density (Fig. 3B and Table 1). These vessels
were functional as assessed by the greater perfusion observed upon
injection of a contrast agent (Fig. 3D). Whether increased angio-
genesis was promoted by the infiltrating macrophages, as previously
suggested (30), remains to be determined.
Next, we interrogated whether the effect of Saa3 ablation on
stroma remodeling improved the therapeutic benefit of current
drug treatments. As illustrated in Fig. S3F, Saa3-null mice ex-
hibit a slight survival advantage when treated with either gem-
citabine alone (50 mg/kg, i.p., twice weekly) or with gemcitabine
in combination with clodronate, a macrophage-depleting agent.
Similar results were obtained when we combined gemcitabine
with B20.4.1.1, an anti-VEGF monoclonal antibody (Fig. S3F).
However, the differences were not statistically significant.
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Fig. 2. Transcriptional profiling of CAFs. (A) Heat map representing color-
coded expression levels of differentially expressed inflammatory genes in
CAFs (n = 5) vs. NPFs (n = 3). The heat map was generated from differential
expression analysis, in which data were sorted by FPKM (fragments per
kilobase of transcript per million mapped reads) expression value and
log2 fold change with a q-value ≤0.05. The specific inflammatory gene set
was selected from publicly available databases. (B) GSEA of CAFs signifi-
cantly up-regulated in inflammatory and cell-adhesion pathways.














Saa3-Null Tumor Cells Have Increased Migratory but Not Homing
Properties. Tumors lacking Saa3 appeared less differentiated
upon hematoxylin and eosin (H&E) and CK19 staining (Fig.
4A). The undifferentiated tumor phenotype has been associated
with a cancer stem-like state in pancreatic cancer (31). There-
fore, we assessed the cancer stem cell (CSC) compartment in
Saa3-competent and Saa3-null tumors. As illustrated in Fig. 4B,
we found a marked increase in CSC (CD133+) and metastatic
CSC (CD133+/CXCR4+) populations in Saa3-competent PDAC
tumors vs. those lacking Saa3 expression (0.56% vs. 4.02%
CD133+ cells and 0.15% vs. 0.43% in CD133+/CXCR4+ cells,
respectively) (Table 1). These results suggest that the absence of
Saa3 confers a more invasive phenotype (32). Indeed, Saa3-null
tumors showed a higher Ki67 proliferation index (Fig. 4C). In
addition, EYFP+ tumor cells present in the pancreas of 8-wk-old
Saa3-null mice displayed a considerably higher percentage of
PDGFRα+ cells than those expressing Saa3 (2.43% vs. 0.21%,
respectively) (Fig. 4D and Table 1). Since PDGFRα expression is
a marker for epithelial-to-mesenchymal transition (EMT), these
results suggest that the absence of Saa3 expression might pro-
mote the appearance of a migratory phenotype (33–35).
Since PDAC tumor cells most frequently metastasize to the liver,
we examined the presence of Saa3-competent and Saa3-null EYFP+
pancreatic tumor cells in this tissue. As illustrated in Fig. 4E and Fig.
S4A, we detected an unusually high number of disseminated tumor
cells in the liver of KPeCY Saa3-null animals, representing as many
as 15.3% of all liver cells. In contrast, the number of tumor cells in
Saa3-competent animals represented only 0.07% of the liver cell
population (Fig. 4E, Table 1, and Fig. S4A). However, these dis-
seminated Saa3-null tumor cells did not proliferate and failed to
propagate after colonization (Fig. S4B). Indeed, whereas 12 of 63
Saa3-competent mice (19%) displayed metastatic outgrowths, only
2 of 40 Saa3-null animals (5%) presented with metastatic lesions in
their livers (P = 0.043) (Table 1). These reduced levels of metastatic
outgrowth were not due to a reduction in the inflammatory cell
population, CD11b+ and F4/80+ monocyte-derived immune cells,
which are known to establish the metastatic niche (Fig. S4C) (36,
37), and thus suggest that the reduced metastatic potential of Saa3-
null tumors is an intrinsic property of the tumor cells. Indeed, these
infiltrated Saa3-null tumor cells were negative for Ki67 immunos-
taining, indicating that they have limited proliferative properties
(Fig. S4B). However, it is also possible that absence of Saa3 ex-
pression in the liver may contribute to the limited proliferative and
metastatic properties of these tumor cells.
It has been reported that Saa1 is a potent inducer of liver
metastasis (26). In addition, SAA1 is among the top 50 up-
regulated genes in the metastatic liver expression profile in a
human PDAC dataset analyzed by Moffitt et al. (7), suggesting
that SAA1 may be relevant in liver metastasis formation. Thus,
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Fig. 3. Characterization of the stromal component of Saa3-null tumors. (A, Left)
Masson’s trichrome and Sirius Red staining of collagen in Saa3-competent
(WT) and Saa3-null (KO) tumors. (Scale bars, 50 μm.) (Right) Quantitative
analysis of Masson’s trichrome-stained sections of Saa3-competent (WT) and
Saa3-null (KO) tumors (n = 4). (B, Left) Representative images of F4/80 and
CD31 immunostaining in Saa3-competent (WT) and Saa3-null (KO) tumors. (Scale
bars, 50 μm.) (Right) Quantitative analysis of F4/80- and CD31-stained sections of
Saa3-competent (WT) and Saa3-null (KO) tumors (n = 5). (C, Left) FACS analysis of
fresh Saa3-competent (WT) and Saa3-null (KO) tumor samples with anti-F4/80
and anti-CD11b antibodies. (Center) FACS analysis of F4/80+/CD11b+ double-
positive macrophages with anti-CD11c and anti-CD206 antibodies. The percent-
age of M1 (CD11chigh/CD206low) (blue square) and M2 (CD11clow/CD206high) (red
square) macrophage populations is indicated for each tumor type. (Right)
Quantitative analysis of M1 and M2 macrophages in Saa3-competent (WT) and
Saa3-null (KO) tumors (n = 2). (D, Left) Micro-ultrasound images of Saa3-
competent (WT) and Saa3-null (KO) tumors after injection of contrast agent.
(Right) Quantitative analysis of vessel density in Saa3-competent (WT) and
Saa3-null KO) tumors (n = 5). *P < 0.05; **P < 0.001; ***P < 0.001.
Table 1. Most relevant features of Saa3-competent (WT) and
Saa3-null (KO) KPeCY mice




Macrophage number and infiltration + ++++
Other immune cell infiltration + +
CAFs
Tumor growth support +++ −








Migratory tumor cells + ++++
Grading of the phenotypes is illustrated from not observed (–) to low (+),
normal (++), high (+++), or very high (++++).
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in livers of Saa3-competent and Saa3-null tumor-bearing mice
killed at the humane end point. As illustrated in Fig. S4D, the
levels of expression of Saa1 and Saa2 are high in the livers of
Saa3-competent, but not in Saa3-null, tumor-bearing mice. These
results may also contribute to explaining why the abundant pan-
creatic tumor cells present in the livers of Saa3-null mice have
limited metastatic potential.
To better characterize the effect of Saa3 ablation on the mi-
gratory properties of PDAC tumor cells, we generated cell lines
from pancreatic tumors lacking this protein. FACS analysis con-
firmed that the number of CD133+/CD44+ CSCs was higher in
Saa3-null EYFP+ tumor cell lines (46.6 vs. 18.8%) (Fig. 4F and
Table 1), demonstrating a clear enrichment in this population (32,
38). Migration assays revealed that tumor cells lacking Saa3 dis-
played increased migratory properties (Fig. 4G and Table 1).
While Saa3-expressing tumor cells advanced toward the scratch as
a solid layer, cells lacking Saa3 moved freely throughout the
scratch as individual cells (Fig. 4G). CAFs lacking Saa3 expression
also had increased motility and closed the gap more efficiently
than those expressing the protein (61.5% in Saa3-null vs. 40.8% in
wild-type CAFs in a 16 h period) (Table 1 and Fig. S4E).
Saa3 Is Required for the Protumorigenic Properties of CAFs. To
characterize the effect of Saa3 on the interaction between pan-
creatic tumor cells and CAFs, we examined the growth properties
of organoids generated from PDAC tumors of KPeCY mice
cocultured with CAFs expressing or lacking Saa3. As illustrated in
Fig. 5A, Saa3-expressing CAFs significantly increased the number
and size of individual organoids (Fig. 5A). In contrast, Saa3-null
CAFs failed to promote tumor growth resulting in organoid cul-
tures similar to those grown in the absence of CAFs (Fig. 5A and
Table 1). As expected, NPFs effectively reduced the growth of
organoids. These results clearly indicate that Saa3 plays a key role
on the ability of CAFs to support tumor cell growth.
To explore the effect of Saa3 in the cross talk between tumor cells
and CAFs in vivo, we orthotopically inoculated immunocompro-
mised mice with CAFs as well as with tumor cells (0.5 × 106 each)
either expressing or lacking Saa3 in (Fig. 5B). As illustrated in Fig.
5C, ablation of Saa3 in tumor cells (n = 6) had no effect on their
ability to induce tumors. As expected, based on the results described
above using in vitro assays, coinjection of Saa3-expressing tumor
cells with NPFs (n = 6) reduced tumor growth whereas coinjection
with Saa3-expressing CAFs (n = 8) led to a significant increase in
tumor volume. Interestingly, when these tumor cells were coinjected
with CAFs lacking Saa3 (n = 8), tumor growth was significantly
reduced to levels even lower than those observed with NPFs, in-
dicating that Saa3 is essential for the ability of CAFs to stimulate
tumor growth in vivo. However, this effect was not observed when
we coinjected Saa3-null tumor cells along with Saa3-null CAFs (n =
6) (Fig. 5C and Table 1). No significant differences were observed in
the proliferation (Ki67 and Phospho-HistoneH3) or apoptosis
(cleaved caspase 3) levels that could explain the differences in tumor
volume induced by Saa3-competent vs. Saa3-null CAFs (Fig. S5).
These observations indicate that, whereas Saa3 provides protu-
morigenic properties to CAFs, the antitumorigenic effect of Saa3-
null CAFs requires that the corresponding tumor cells express the
Saa3 protein. Likewise, we also observed a protumorigenic effect
when we coinjected Saa3-null tumor cells with Saa3-null CAFs,
suggesting that when both cell types are deficient in Saa3 expression
there is an alternative cross talk that promotes tumor progression.
These results provide an explanation as to why tumor development
in Saa3-null mice is not affected, since the potential tumor-
inhibitory effect of Saa3 ablation in CAFs does not take place
when their neighboring tumor cells also lack Saa3.
Saa3 Ablation Alters the Transcriptional Profile of CAFs and Tumor
Cells. To dissect the mechanism by which Saa3 confers tumor stim-
ulatory properties to CAFs, we used RNAseq to compare the
transcriptome of Saa3-null and Saa3-proficient CAFs. GSEA path-
way analysis of Saa3-null CAFs revealed a significant enrichment in
Proliferation and Angiogenesis hallmarks, as well as up-regulation of
Sonic Hedgehog, TNFα/NFκB, and IL-6 pathways. Moreover, we
observed enrichment in genes implicated in EMT, suggesting in-
creased plasticity of Saa3-null CAFs as well as their potential effect
in inducing an undifferentiated phenotype in their neighboring tu-
mor cells (39). In addition, the Saa3-null CAFs displayed up-
regulation of the apical junction pathway, a property that predicts
increased physical contact between stromal and tumor cells (22).
The most down-regulated gene sets included the oxidative
phosphorylation and drug metabolism and cholesterol homeostasis
(Fig. 6A). Moreover, loss of Saa3 expression also down-regulated
other metabolic pathways such as Glycolysis. This pathway is acti-
vated in Saa3-competent CAFs, possibly playing a role in providing
metabolites to their neighboring tumor cells (25). These observa-
tions suggest that loss of Saa3 might induce metabolic reprogram-
ming of CAFs along with a reduction in the production of
nutritional metabolites available to the adjacent tumor cells.
We also studied the transcriptomes of Saa3-competent and Saa3-
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Fig. 4. Phenotypic properties of Saa3-null tumor cells. (A) H&E staining
(Upper) and CK19 immunostaining (Lower) of Saa3-competent (WT) and
Saa3-null (KO) tumors. (Scale bars, 50 μm.) (B) FACS analysis of fresh tumor
samples of Saa3-competent (WT) and Saa3-null (KO) tumors from KPeCY
mice with anti-CD133 and anti-CXCR4. (C) Quantitative analysis of Ki67+ cells
in Saa3-competent (WT) and Saa3-null (KO) tumor sections. (D) FACS analysis
of EYFP-expressing PDGFRα+ pancreatic tumor cells in pancreas isolated from
8-wk-old Saa3-competent (WT) and Saa3-null (KO) KPeCY mice. (E) FACS
analysis of EYPF-expressing cells in livers isolated from the same mice.
(F) FACS analysis of pancreatic tumor cell lines with anti-CD133 and anti-
CD44. (G, Left and Center) Migratory properties of Saa3-competent (WT) and
Saa3-null (KO) tumor cells in an in vitro scratch assay. (Right) A color-
enhanced picture for better visualization. *P < 0.05.














expression in pancreatic tumor cells results in a significant enrichment
of cell cycle- and metabolism-related gene sets, thus confirming the
increased proliferative capacity of the Saa3-null tumor cells. In ad-
dition, these mutant tumor cells displayed up-regulation of the tight
junction pathway, suggesting deregulated cell-to-cell contact proper-
ties. On the other hand, we observed significant down-regulation in
ECM reorganization-related pathways, suggesting a decrease in the
levels of extracellular collagen, a feature that might explain the higher
migratory properties of Saa3-null tumor cells (Fig. S6A).
Saa3 is involved in the regulation of several inflammatory cyto-
kines (26, 27). Thus, we examined the profile of cytokine enrichment
changes by GSEA analysis utilizing a specific signature of 144 cyto-
kines. As illustrated in Fig. 6B, elimination of Saa3 down-regulated
the global cytokine profile not only in CAFs but also in the tumor
cell compartment. Taken together, these results indicate that elim-
ination of Saa3 induces proliferation, metabolic reprogramming,
and cell-to-cell contact in both CAFs and tumor cell population. On
the other hand, lack of Saa3 reduces overall cytokine secretion with
the exception of the TNFα and IL-6 pathways in CAFs.
Mpp6 Down-Regulation Reverts the Antitumorigenic Properties of
Saa3-Null CAFs. Differential expression analysis of the above
dataset revealed the presence of three significantly up-regulated
genes in Saa3-null CAFs. In particular, the gene encodingMPP6 (fold
change = 15.8), a member of the palmitoylated membrane protein
subfamily of peripheral membrane-associated MAGUK guanylate
kinases (Fig. 6 C and D). The other up-regulated genes included
those encoding the γ-aminobutyric acid receptor 3 (GABRA3; fold
change = 3.2) and Cbl, an E3 ubiquitin–protein ligase involved in cell
signaling and protein ubiquitination (fold change = 2.3) (Fig. 6C).
These observations were validated forMpp6 using qRT-PCR analysis
of Saa3-null and -competent CAFs (Fig. S6B).
To determine whether Mpp6 up-regulation was functionally re-
sponsible for the antitumorigenic effect of Saa3-null CAFs, we
knocked downMpp6 expression using specific shRNAs that resulted
in a significant decrease of its expression levels. Mpp6–down-
regulated Saa3-null CAFs were coinjected orthotopically with Saa3-
competent PDAC tumor cells (n = 4). These tumor cells grew
significantly faster than those coinjected with Saa3-null CAFs (n =
8), reaching proliferation levels similar to those observed with Saa3-
competent CAFs (Fig. 6E). Down-regulation ofMpp6 also reverted
the undifferentiated phenotype of tumor cells in the presence of
Saa3-null CAFs (Fig. 6F). These observations, taken together, in-
dicate that the growth-inhibitory activity of Saa3-null CAFs on their
adjacent tumor cells is mediated by the up-regulation of the tight
junction protein Mpp6. Interestingly, Saa3 ablation did not alter the
levels of expression of Mpp6 in pancreatic tumor cells (Fig. 6D),
indicating that Saa3 selectively controls the expression of Mpp6 in
CAFs. These observations open the door to future therapeutic
strategies aimed at up-regulating Mpp6 expression.
SAA1, the Functional Human Ortholog of Saa3, Is Up-Regulated in a
Subpopulation of Human CAFs Associated with Poor Clinical Outcome.
The human genome contains three genes encoding highly related
SAA family members (40% amino acid identity): SAA1, SAA2,
and SAA4 (40). It also contains a nonfunctional SAA3 pseudogene
(SAA3P) (41). Among the three SAA functional genes, SAA1 is the
most similar in structure and function to murine Saa3. The
SAA1 protein is expressed in several stromal cell types including
activated synovial fibroblasts (42). Moreover, SAA1 has been
shown to control neutrophil plasticity and has anti- and protu-
morigenic inflammatory properties in melanoma (43). SAA1 is
highly expressed in a variety of tumors including PDAC [The
Cancer Gene Atlas (TCGA) database]. Moreover, SAA1 is the
SAA family member most highly expressed in CAFs of PDAC
tumors (Fig. 7A). To further confirm these observations, we ex-
amined the SAA1 expression levels in the PDAC RNAseq and
microarray dataset recently published by Moffitt et al. (7). RNAseq
data revealed high but variable expression of SAA1 both in tumors
and in CAFs isolated from PDAC samples (Fig. 7B). Moffitt’s re-
port described two types of PDAC-associated stroma, “normal” and
“activated,” based on stromal signatures considering high αSMA
expression or an inflammatory signature, respectively (7). Although,
SAA1 was found to be expressed primarily in tumor samples with an
“activated” stroma signature, high levels of SAA1 expression cor-
related with significantly worse survival in tumor samples containing
either “normal” or “activated” stroma (Fig. 7C). In those tumor
samples that contained low amounts of stroma, high SAA1 ex-
pression correlated with a slight increase in survival, suggesting that
the protumoral effect of SAA1 overexpression is primarily mediated
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Fig. 5. Cross talk between pancreatic tumor cells and CAFs in the presence
and absence of Saa3. (A, Upper) Cultures of EYFP tumor organoids grown in
the presence of NPFs or Saa3-competent (WT) or Saa3-null (KO) CAFs. (Scale
bars, 100 μm.) (Lower) Quantification of area (Left) and number of organoids
(Right) under the indicated culture conditions. (B) Diagram depicting the in
vivo orthotopic tumor assays in immunodeficient mice carried out to de-
termine the protumorigenic properties of Saa3-competent (WT) (red) and
Saa3-null KO) (light blue) CAFs on pancreatic tumor cells isolated from Saa3-
competent (WT) (yellow) and Saa3-null (KO) (green) tumors. (C) Quantitative
analysis of orthotopic tumor growth in immunodeficient mice inoculated
with the indicated combinations of Saa3-competent (WT) and Saa3-null
(KO) CAFs and pancreatic tumor cells. Color coding is as in B. NPFs (open
bar) were used as a negative control. *P < 0.05; **P < 0.001; ***P < 0.001.
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by the stromal cells. In addition, SAA1 was identified among the top
50 genes of Moffitt’s liver-specific metastatic signature in PDAC.
Analysis of freshly isolated CAFs from tumor samples of
PDAC patients (n = 7) and from adjacent normal pancreas (n =
5) revealed that SAA1 is up-regulated in the CAF samples
compared with those obtained from normal pancreata (log2 fold
change = 3.74; Padj < 0.005). In contrast, the levels of MPP6
expression were lower in CAFs than in normal pancreatic fi-
broblasts (Fig. 7D). That is, the levels of both genes, SAA1 and
MPP6, inversely correlated in both types of fibroblasts (Fig. 7E).
Similar results were obtained with Moffitt’s dataset (Fig. S6C).
These results support the concept that SAA1 may play a role in
human PDAC similar to that described for Saa3 in GEM tumors.
Discussion
PDAC is characterized by a rich desmoplastic stroma composed
mainly of a heterogeneous population of CAFs. A CAF sub-
population characterized by expressing PDGFRα is thought to
mediate an inflammatory response (21). However, their putative
protumorigenic activity has not been properly documented.
Here, we show that PDGFRα+ CAFs possess protumorigenic
properties in vivo based on their ability to promote the growth of
coinjected pancreatic tumor cells in immunocompromised mice.
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Fig. 7. SAA1 and MPP6 expression in human PDAC tumors. (A) Normalized
gene-expression values of SAA family members in human NPFs (open bars)
and CAFs (solid bars) by RNAseq. (B) FPKM values of SAA1 expression by
RNAseq in human CAFs and PDAC samples obtained from Moffitt’s dataset
(7). (C) Kaplan–Meier survival analysis of PDAC patients with high (red) or
low (blue) SAA1 expression levels classified by the presence of activated
(Top) or normal (Middle) stroma signatures and in PDAC tumors with low
stroma content (Bottom) based on microarray data from Moffitt’s dataset
(7). (D) SAA1 (Upper) and MPP6 (Lower) expression in freshly sorted human
NPFs (open bars) (n = 5) and CAFs (solid bars) (n = 7). (E) Correlation of SAA1
and MPP6 expression in freshly sorted human CAFs (solid circles) (n = 7) and
human NPFs (open circles) (n = 5). Spearman’s correlation (Corr) and the
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Fig. 6. Transcriptional profiling of Saa3-null CAFs and pancreatic tumor
cells. (A) GSEA pathway analysis of Saa3-null vs. Saa3-proficient CAFs. The
normalized enrichment score (NES) ranking was generated by the GSEA.
(B) GSEA analysis of a specific cytokine signature (144 cytokines) in Saa3-null
(KO) CAFs and pancreatic tumor cells. (C) Heat map of the differentially
expressed genes in Saa3-null (KO) CAFs compared with Saa3-competent (WT)
CAFs. (D) RNAseq analysis of Mpp6 expression in Saa3-competent (WT, solid
bars) and Saa3-null (KO, open bars) CAFs and tumor cells. (E) Tumor growth
of orthotopic allografts of immunocompromised mice of Saa3-competent
(WT) and Saa3-null (KO) pancreatic tumor cells in the presence of Saa3-
competent (WT) and Saa3-null (KO) CAFs treated (+) or nontreated (−) with
a shRNA against Mpp6. Tumor volume is indicated by solid (WT cells), open
(KO cells), and mixed solid/open (WT and KO cells) bars. (F) Images of H&E
and CK19 staining of orthotopic tumors illustrated in E. (Scale bars, 100 μm.)
**P < 0.001.














PDAC tumors, since the corresponding PDGFRα+ fibroblasts
isolated from normal pancreata inhibited tumor growth.
Recent studies have described distinct populations of CAFs (6,
8, 44). A subpopulation designated as “myCAFs” is characterized
by elevated expression of αSMA and appears to localize imme-
diately adjacent to the neoplastic cells. A distinct subpopulation,
iCAFs, is located more distantly from the neoplastic cells and
expresses low levels of αSMA. Instead, these cells display higher
levels of secreted IL-6 and other inflammatory mediators (44).
The CAFs isolated in our study, based on the expression of
PDGFRα, also have high levels of IL-6, suggesting that they may
represent iCAFs. Other similarities between these iCAFs and the
PDGFRα+ CAFs isolated here include significant up-regulation
of cytokine/chemokine receptor-signaling pathways and JAK-
STAT signaling. However, the PDGFRα+ CAFs characterized
in this study display significant overexpression of innate immune
response-related signaling and high enrichment in cell-to-cell
junction pathways, two properties not reported in iCAFs, thus,
suggesting that the PDGFRα+ CAFs described here might rep-
resent yet another subpopulation of inflammatory CAFs.
Transcriptome analysis of the PDGFRα+ CAFs studied here
revealed a series of selectively up-regulated genes compared with
those fibroblasts present in normal pancreata. The top-scoring
gene was Saa3, a member of the gene family encoding Saa pro-
teins. In humans, SAA1 and SAA2 are secreted during the acute
phase of inflammation and have been implicated in several chronic
inflammatory diseases, such as rheumatoid arthritis, atherosclero-
sis, and amyloidosis. Another member of this gene family, SAA3, is
not expressed in human cells but has been shown to be a major
acute-phase reactant in other species such as rabbits and rodents
(16, 45). Murine Saa3 has been shown to be expressed in macro-
phages (46) and adipose tissue (47). During inflammatory pro-
cesses, Saa3 expression is effectively induced by Il-1β, Tnfα, and
Il-6 through NFκB signaling. Interestingly, these cytokines, as well
as the NFκB pathway, were found to be significantly up-regulated
in our CAF dataset. Finally, a fourth member of this gene family,
SAA4, appears to be expressed constitutively in the liver (48).
Germline elimination of Saa3 had no effect of PDAC devel-
opment, as reflected by the similar number of lesions observed in
Saa3-null mice and by the lack of benefit in survival. However,
Saa3-null tumors exhibit stroma remodeling, including reduced
fibrosis and ECM, infiltrating macrophages, and increased vessel
density. Indeed, Saa3-null CAFs had an elevated angiogenesis
signature as revealed by GSEA pathway analysis. It has been
suggested that increased vessel density along with a reduction in
fibrosis may improve the efficacy of chemotherapy treatments (23,
49, 50). However, we did not observe a significant increase in the
therapeutic benefit of tumor-bearing Saa3-null mice treated with
gemcitabine alone, with gemcitabine in combination with clodro-
nate, or with an anti-VEGF monoclonal antibody.
Saa3-null tumors were also less differentiated and more invasive,
as suggested by a higher proliferation index and increased numbers
of pancreatic CD133+ CSCs (32, 38). In addition, Saa3-null tumor
cells showed an enhanced migratory phenotype. We observed an
unexpected abundance of Saa3-null tumor cells in the liver, consti-
tuting as much as 15% of all liver cells, during the early stages of
pancreatic tumor development. However, these migrating tumor
cells did not elicit metastatic outgrowths, possibly due to their ob-
served lack of proliferative capacity within the Saa3-null liver mi-
croenvironment. Whether this migratory phenomenon is an intrinsic
property of the Saa3-null tumor cells or is a consequence of the
absence of this protein in liver tissue and/or in prometastatic mac-
rophages remains to be determined. Interestingly, we observed that
the absence of Saa3 in liver tissue of tumor-bearing mice inhibits the
expression of the Saa1 and Saa2 isoforms. Since SAA1 has been
described as a potent inducer of liver metastasis (7, 26), the reduce
levels of expression of Saa1/Saa2 in Saa3-null livers could explain
why the abundant disseminated pancreatic tumor cells cannot form
metastatic foci. Conditional ablation of Saa3 expression in specific
cell populations, including tumor cells, CAFs, macrophages, and
possibly other immune cells, should help to better define the role of
Saa3 during the various stages of tumor development.
Saa3 is required for the protumorigenic properties of CAFs. In-
deed, orthotopic coinjection of Saa3-null CAFs with Saa3-compe-
tent tumor cells in the pancreas of nude mice significantly reduced
tumor size. The inhibitory effect of Saa3-null CAFs was even more
pronounced than that induced by NPFs. However, this inhibitory
effect was not observed when we used Saa3-null tumor cells. Since
loss of Saa3 expression had no significant effect on the tumorigenic
properties of pancreatic tumor cells, the observed lack of an anti-
tumorigenic effect of Saa3-null CAFs on Saa3-null tumor cells must
be due to defective cross talk between Saa3-null tumor cells and
Saa3-null CAFs. These results were also observed in vitro using
tumor organoids, ruling out a putative role of a third cellular partner
in this cross talk. These reconstruction experiments recapitulate the
results obtained with Saa3-null mice in which both CAFs and tumor
cells are devoid of Saa3, thus explaining why PDAC development is
unaffected in Saa3-null mice. Taken together, these results un-
derscore the critical role for Saa3 in mediating the interaction be-
tween CAFs and tumor cells and predict that selective elimination of
Saa3 in CAFs might provide significant therapeutic benefit. Future
studies using conditional ablation of Saa3 should help better define
the protumorigenic role of Saa3 in CAFs.
Comparative transcriptional profiling of tumor cells and CAFs
expressing or lacking Saa3 revealed that Saa3-null cells display an
increased proliferative signature and metabolic reprogramming and
could suggest altered heterotypic cell-to-cell contact. Moreover,
Saa3-deficient CAFs show reduced overall cytokine secretion, with
the exception of the TNFα and IL-6 pathways. This result was
unexpected, since acute-phase SAA apolipoproteins have been
reported to enhance the expression of inflammatory cytokines, in-
cluding IL-1β, IL-6, TNFα, IL-8, and G-CSF (51–53). Likewise,
proinflammatory cytokines such as IL-1β, IL-6, and TNFα induce
the synthesis of these SAA proteins (54). Therefore, up-regulation
of TNFα, NFκB, and IL-6 pathways may result from an effort by
the Saa3-null cells to induce the expression of Saa3, thereby gen-
erating an inflammatory loop. Finally, the reduction of glycolysis
and the down-regulation of cholesterol homeostasis in Saa3-null
CAFs, shown by GSEA pathway analysis, could contribute to their
inhibitory activity on tumor cells observed in orthotopic coinjection
experiments, by reducing nutrient transport.
Comparative analysis of Saa3-competent and Saa3-null CAFs
revealed minor changes in their transcriptome. However, we iden-
tified three overexpressed genes in Saa3-deficient CAFs. Of partic-
ular interest wasMpp6, a member of the peripheral MAGUK family
of proteins primarily involved in controlling epithelial cell polarity
(55, 56). Mpps also function in tumor suppression and receptor
clustering by forming multiprotein complexes containing distinct sets
of transmembrane, cytoskeletal, and cytoplasmic signaling proteins
(57). Interestingly, Mpp6 overexpression appears to be responsible
for the loss of the protumorigenic effect of Saa3-null CAFs. Indeed,
knockdown ofMpp6 expression in these mutant CAFs restored their
protumorigenic properties, as determined in coinjection studies with
Saa3-proficient pancreatic tumor cells in nudemice. Interestingly, the
expression levels of Mpp6 were unaffected by the presence or ab-
sence of Saa3 in tumor cells, suggesting that the functional re-
lationship between Saa3 and Mpp6 might be limited to CAFs.
Understanding the molecular pathways implicated in the inhibitory
role of Mpp6 on the protumorigenic effect of CAFs should unveil
novel therapeutic opportunities.
Finally, we have interrogated whether our observations in GEM
PDAC tumor models could be translated to a human scenario. As
indicated above, the SAA3 locus is a nonexpressed pseudogene
(41, 58). On the other hand, the acute-phase SAA1 protein has
structural and functional characteristics that closely resemble
those of murine Saa3, suggesting that SAA1 and Saa3 could be
ortholog proteins (59). Indeed, SAA1 is overexpressed in human
CAFs compared with NPFs. Moreover, high levels of SAA1 ex-
pression in the stromal component of human PDAC tumors
correlate with significantly worse survival regardless of whether
the tumor samples contain “normal” or “activated” stroma.
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However, high SAA1 expression in tumor samples with low stroma
content also correlate with slightly increased survival, suggesting
that SAA1 may have a protumoral effect when highly expressed in
stroma and a possible antitumor effect when overexpressed in
tumor cells. A dual role for SAA proteins depending on cellular
context has already been reported by other investigators (18, 60).
Finally, MPP6 levels inversely correlated with SAA1 expression in
human PDAC samples. Therefore, our results support the con-
cept that murine Saa3 may serve as a model to study the role of
the human acute-phase SAA1 protein in pancreatic cancer and to
develop novel therapeutic strategies against this potential target.
Since SAA1 is a secreted protein, it is conceivable that its pro-
tumorigenic properties could be dwarfed by specific monoclonal
antibodies, providing that they are primarily delivered to the
desmoplastic stroma, avoiding as much as possible their in-
teraction with the tumor cells. In addition, a better understanding
of the signaling pathways driven by SAA1 should provide clues
about differential signaling mechanisms in stromal vs. tumor cells.
Materials and Methods
Mice. The K-Ras+/LSLG12Vgeo;Trp53lox/lox;Elas-tTA/tetO-Cre strain has been
previously described (20). Rosa26+/LSLEYFP mice were obtained from The
Jackson Laboratory (MGI: 2449038). Saa3-null sperm [Saa3tm1(KOMP)Vlcg] was
obtained from the KOMP Repository (https://www.komp.org/geneinfo.php?
geneid=78011) and was used to generate Saa3-null mice by in vitro fertil-
ization of KPeCY females at the Spanish National Cancer Research Centre
(CNIO) Transgenic Unit. Mice were maintained in a mixed 129/Sv-C57BL/6
background. Immunodeficient NU-Foxn1nu mice (5-wk-old females) were
purchased from Harlan Laboratories. All animal experiments were approved
by the Ethical Committees of the CNIO, the Carlos III Health Institute, and the
Autonomous Community of Madrid and were performed in accordance with
the guidelines stated in the International Guiding Principles for Biomedical
Research Involving Animals, developed by the Council for International Or-
ganizations of Medical Sciences. All strains were genotyped by Transnetyx.
Human Samples. Primary tumors were obtained from the Virgen de la
Arrixaca Hospital. Specific informed consent for tumor implantation in mice
was obtained from all patients, and the study received the approval of the
CNIO Ethics Committee. Additional tumors used to isolate the different cell
populations by cell sorting were obtained from patients at the University
Hospital. This part of the study was approved by the ethical committee
of the University of Heidelberg and was conducted in accordance with
the Helsinki Declaration. Written informed consent was obtained from
all patients.
Isolation of CAFs, NPFs, and Tumor Cells. Mouse NPFs, CAFs, and tumor cells
were obtained by mechanical dissociation of freshly dissected tumor tissue as
previously described (61). Single-cell suspensions were immunostained with
APC anti-mouse CD31 (1:200; clone MEC 13.3; BD Biosciences), APC anti-
mouse CD45 (1:200; clone 30-F11; BD Biosciences), FITC anti-mouse CD326
(EpCAM; 1:200; clone: G8.8; BioLegend), and PE anti-mouse CD140a
(PDGFRα; 1:100; clone: APA5; eBioscience). Samples were applied to an Influx
cell sorter (BD Pharmingen) and were separated directly into TRIzol (RNA
isolation) or PBS (cell culture). Analysis was performed by FlowJo software
(Tree Star). Human CAFs and NPFs were obtained from fresh primary PDAC
specimens and adjacent normal pancreas by cell sorting and were immu-
nostained with FITC anti-human CD326 (EpCAM; 1:11; clone: AC128; Miltenyi
Biotec); VioBlue anti-human CD45 (1:11; clone: 5B1; Miltenyi Biotec); and
APC anti-human CD31 (1:11; clone: HEA-125; Miltenyi Biotec). Fibroblasts
were defined as the EpCAM−/CD45−/CD31− population. RNA extraction and
library preparation were performed as described elsewhere (62).
RNAseq, Gene-Expression Profiling, and GSEA Analysis. Total RNA extracted
from mouse cells by the Qiagen RNeasy Mini Kit enriched by polyA pull-down
was used to prepare a cDNA library using the Illumina TruSeq RNA Library
Preparation Kit. Libraries were sequenced with Illumina HiSeq 2000 at Co-
lumbia Genome Center. Reads were analyzed with the Nextpresso pipeline
(63). Sequencing quality was checked with FastQC v0.11.0 (www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Reads were aligned to the human genome
(GRCh37/hg19) with TopHat 2.0.10 using Bowtie 1.0.0 (64) and SAMtools 0.1.1.9
(65), allowing two mismatches and 20 multihits. GSEA was performed with
GSEAPreranked (66), setting 1,000 gene set permutations. RNAseq data are
available online in the National Center for Biotechnology Information (NCBI) Geo
Database (GSE106901). Only gene sets with significant enrichment levels
(FDR q-value <0.25) were considered. Human RNA extraction and library
preparation were performed as described elsewhere (62).
S.c. and Orthotopic Allograft Models. Tumor (0.5 × 106) cells only or in combi-
nation with 0.5 × 106 CAFs or NPFs were injected in PBS:Matrigel (1:1) into the
dorsal flanks of the mice. Growth was measured every 3 d until the humane end
point. Orthotopic injection was performed by surgery under anesthesia (4%
isofluorane) using the same number of cells for injection as in the s.c. model.
Tumor growth was monitored by micro-ultrasound (Vevo 770; VisualSonics).
Mice were killed 3 wk postinjection. Tumor volume was limited to 1,500 mm3.
Tumors were measured by caliper and calculated as length × width2/2.
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